Please try another search
Dancann Pharma A/S reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was DKK 1.61 million compared to DKK 1.78 million a year ago. Net loss was DKK 2.92 million compared to DKK 5.62 million a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 1.86 | 1.02 | ||
Gross Profit | -0.346 | -1.43 | ||
Operating Income | -3.09 | -2.86 | -4.23 | |
Net Income | -2.75 | -3.53 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 67.7 | 68.56 | ||
Total Liabilities | 10.37 | 9.83 | ||
Total Equity | 60.48 | 57.34 | 58.74 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | 0 | -3.92 | -8.34 | -3.69 |
Cash From Investing Activities | -1.45 | -1.74 | ||
Cash From Financing Activities | 1.22 | 0.367 | ||
Net Change in Cash | -4.15 | -5.06 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review